BioSyent (CVE:RX) Sets New 1-Year High – What’s Next?

BioSyent Inc. (CVE:RX) reached a new 52-week high during trading on Tuesday . The stock traded as high as C$15.21 and last traded at C$15.21, with a volume of 2320 shares trading hands. The stock had previously closed at C$14.66.

Wall Street Analyst Weigh In

Separately, Bloom Burton upgraded BioSyent from a “moderate buy” rating to a “strong-buy” rating in a report on Friday, November 21st. One equities research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, the company currently has an average rating of “Strong Buy”.

BioSyent Price Performance

The company has a debt-to-equity ratio of 2.90, a quick ratio of 6.91 and a current ratio of 3.92. The company has a 50-day moving average price of C$13.22 and a 200-day moving average price of C$12.12. The firm has a market capitalization of C$177.96 million, a P/E ratio of 21.12 and a beta of 0.52.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.